rna
interfer
rnai
mechan
select
degrad
messeng
rna
mrna
express
emerg
potenti
novel
approach
drug
target
valid
studi
function
genom
small
interf
rna
sirna
therapeut
develop
rapidli
alreadi
clinic
trial
ongo
plan
although
challeng
remain
deliveri
strategi
sirna
becom
main
hurdl
must
resolv
prior
fullscal
clinic
develop
sirna
therapeut
articl
provid
overview
current
deliveri
strategi
synthet
sirna
focus
target
selfassembl
nanoparticl
show
potenti
becom
use
effici
tool
cancer
therapi
ever
sinc
rna
interfer
rnai
discov
fire
et
al
technolog
rapidli
becom
power
tool
basic
research
potenti
new
strategi
clinic
trial
small
interf
rna
sirna
produc
cleavag
longer
dsrna
precursor
rnaseiii
endonucleas
dicer
enter
rnainduc
silenc
complex
risc
activ
upon
guid
antisens
strand
select
select
base
rel
thermodynam
stabil
two
duplex
end
least
stabl
duplex
recogn
asymmetr
unwound
piwiargonautezwil
paz
domain
argonaut
multifunct
protein
within
risc
incorpor
strand
act
guid
activ
risc
complex
select
degrad
complementari
mrna
target
oncogen
sirna
could
appli
therapeut
agent
cancer
therapi
howev
due
rel
larg
molecular
weight
polyanion
natur
nake
sirna
freeli
diffus
across
cell
membran
thu
deliveri
system
requir
facilit
sirna
access
intracellular
site
action
success
gene
therapi
highli
depend
deliveri
vector
gener
categor
viral
nonvir
vector
viral
vector
highli
effici
current
still
power
tool
gene
transfect
howev
viral
vector
show
limit
load
capac
difficult
produc
larg
scale
importantli
pose
sever
safeti
risk
due
oncogen
potenti
inflammatori
immunogen
effect
prevent
repeat
administr
overcom
limit
nonvir
vector
emerg
promis
altern
gene
deliveri
number
nonvir
sirna
deliveri
approach
report
vivo
includ
nonhuman
primat
human
primari
consider
decid
drug
deliveri
system
sirna
whether
intend
diseas
target
lend
system
local
administr
case
deliveri
dna
encod
short
hairpin
rna
shrna
nonvir
deliveri
system
nuclear
transloc
dna
often
inadequ
attent
given
nonvir
deliveri
sirna
variou
strategi
deliv
sirna
specif
tissu
organ
system
vivo
follow
system
administr
summar
tabl
deliveri
strategi
classifi
follow
categori
quick
inject
sirna
larg
volum
physiolog
buffer
effect
local
duplex
sirna
liver
rat
administr
vegfspecif
sirna
result
inhibit
patholog
neovascular
due
invas
inject
techniqu
hydrodynamicsbas
transfect
appropri
clinic
applic
point
howev
recent
advanc
use
computercontrol
catheterguid
inject
devic
greatli
improv
precis
reproduc
approach
date
devic
use
deliveri
dna
sirna
equal
applic
approach
sirna
chemic
modifi
backbon
conjug
lipophil
cholesterol
moieti
end
sens
strand
led
suppress
apob
mrna
approxim
liver
iv
inject
soutschek
et
al
report
immun
stimul
offtarget
effect
occur
mice
high
dose
howev
safeti
evalu
potenti
approach
need
studi
recent
studi
indic
cholesterolconjug
sirna
deliv
hepatocyt
complex
lipoprotein
cation
lipid
liposom
cation
polym
cation
dendrim
cation
cellpenetr
peptid
use
deliveri
sirna
common
characterist
among
vector
net
posit
charg
contribut
complex
format
polyanion
nucleic
acid
sirna
interact
neg
charg
cell
membran
nanoparticl
complex
nm
reduc
renal
excret
taken
cell
taken
cell
via
endocytosi
macropinocytosi
consist
aqueou
compart
enclos
phospholipid
bilay
hydrophil
drug
typic
entrap
center
aqueou
layer
bilay
often
contain
lipid
compon
regularli
cation
andor
fusogen
lipid
cholesterol
polyethylen
glycollipid
liposom
particl
stabl
physicochem
characterist
contrast
lipoplex
spontan
form
via
interact
positivelycharg
lipid
negativelycharg
nucleic
acid
lipoplex
prepar
immedi
use
lipoplex
unstabl
lipofectin
rnaifect
oligofectamin
lipofectamin
transit
tko
commerci
avail
potenti
enhanc
sirna
deliveri
vitro
dotap
n
nnn
trimethyl
ammonium
propan
oligofectamin
first
lipid
formul
use
vivo
deliveri
sirna
effect
gene
silenc
mice
cation
liposom
term
solid
nucleic
acid
lipid
particl
snalp
stabil
pegyl
improv
pharmacokinet
also
success
use
deliv
sirna
mice
nonhuman
primat
monkey
apob
markedli
suppress
snalpformul
sirna
furthermor
note
pegyl
liposom
clinic
approv
deliveri
system
doxorubicin
therefor
repres
viabl
option
deliv
sirna
human
polym
peptid
deliveri
systemsof
mani
cation
polym
polyethyleneimin
pei
wide
examin
dna
oligonucleotid
sirna
deliveri
novel
deliveri
strategi
use
pegyl
pei
rgd
argglyasp
peptid
deliv
sirna
target
vegf
demonstr
inhibit
tumor
growth
reduc
angiogenesi
iv
administr
use
polyamidoamin
polym
vivo
might
hinder
owe
nonspecif
toxic
atelocollagen
kda
use
administ
sirna
system
local
tumor
model
vivo
polym
also
abl
effect
deliv
sirna
target
vegf
tumor
vasculatur
orthotop
model
human
testicular
cancer
bone
metastas
xenograft
model
prostat
cancer
cyclodextrin
polyc
deliveri
system
well
toler
even
repeat
dose
fail
elicit
signific
deliveri
systemspecif
antibodi
respons
recent
report
repeat
administr
rvg
rabi
viru
glycoprotein
antivir
sirna
induc
inflammatori
cytokin
antipeptid
antibodi
studi
also
report
first
time
system
deliv
sirnapeptid
conjug
cross
bloodbrain
barrier
bbb
press
releas
quark
pharmaceut
press
releas
fda
recent
approv
clinic
studi
cyclodextrincontain
nanoparticl
formul
sirna
calando
twopart
sirna
deliveri
system
first
compon
linear
cyclodextrincontain
polyc
bind
anion
backbon
sirna
polym
sirna
selfassembl
nanoparticl
size
smaller
nm
diamet
fulli
protect
sirna
nucleas
degrad
serum
nanoparticl
addit
modifi
ad
adamantin
conjug
peg
without
target
ligand
transferrin
sirna
deliveri
system
design
allow
intraven
inject
upon
deliveri
target
cell
target
ligand
bind
membran
receptor
cell
surfac
rnacontain
nanoparticl
taken
cell
endocytosi
intratumor
deliverydirect
local
inject
sirna
without
deliveri
system
tumor
effect
anticanc
approach
vivo
deliveri
sirna
target
rasa
rasc
xenograft
breast
cancer
model
mice
shown
success
reduc
tumor
volum
howev
clinic
tumor
suitabl
local
deliveri
system
approach
describ
necessari
solid
tumor
vivo
local
vivo
electropor
muscleelectropor
use
deliv
sirna
mous
muscl
tissu
golzio
et
al
show
silenc
effect
last
day
administr
sirna
cotransfect
plasmid
encod
gfp
mice
local
deliveri
cnslocal
deliveri
sirna
cn
feasibl
option
target
cnsbase
diseas
though
system
deliveri
strategi
may
clinic
attract
deliveri
sirna
target
subtyp
nmda
receptor
use
intrathec
inject
led
decreas
protein
express
level
rat
brain
use
surfacemodifi
lpd
nanoparticl
deliv
sirna
solid
metastat
tumor
major
compon
deliveri
system
cation
lipid
protamin
cation
polypeptid
interact
neg
charg
sirna
surfac
steric
stabil
introduc
pegyl
prevent
aggreg
result
complex
serum
compon
ligand
attach
distal
end
peg
chain
increas
cellular
bioavail
cation
lipid
necessari
endosom
lysi
intracellular
releas
sirna
mechan
endosom
membran
destabil
like
due
format
ion
pair
complex
cation
lipid
nanoparticl
neg
charg
anion
lipid
endosom
membran
hypothes
xu
szoka
use
anisamid
target
ligand
tumor
cell
express
sigma
receptor
ligand
target
pegyl
lpd
formul
show
signific
increas
cellular
uptak
via
specif
receptormedi
pathway
import
note
function
anisamid
tumor
uptak
sinc
nontarget
lpd
nanoparticl
accumul
tumor
effici
target
particl
surfac
modifi
lpd
nanoparticl
show
strong
enhanc
permeabl
retent
epr
effect
approxim
inject
dose
per
g
tissu
found
tumor
target
formul
also
demonstr
strong
genesilenc
effect
mediat
rnai
figur
see
preliminari
data
show
surfacemodifi
lpd
deliv
sirna
predominantli
tumor
major
uptak
organ
intraven
administr
formul
provid
advantag
high
tumor
target
low
re
uptak
impli
potenti
rnaibas
tumor
therapi
subsequ
studi
confirm
celluar
entri
mechan
target
nanoparticl
via
sigma
receptor
depend
pathway
gene
silenc
activ
significantli
improv
nanoparticl
formul
immunotox
melanoma
cell
target
nanoparticl
show
fourfold
increas
deliveri
effici
compar
nontarget
nanoparticl
addit
free
haloperidol
known
agonist
sigma
receptor
significantli
reduc
deliveri
effici
target
nanoparticl
formul
sinc
cell
stabli
mark
luciferas
gene
use
retroviru
vector
vivo
activ
nanoparticl
formul
assess
luciferas
gene
silenc
whole
tumor
load
lung
target
nanoparticl
silenc
luciferas
activ
wherea
none
control
formul
show
signific
gene
silenc
activ
none
formul
includ
target
nanoparticl
induc
signific
proinflammatori
cytokin
tnf
serum
combin
three
differ
sirna
sequenc
weight
ratio
differ
formul
evalu
therapeut
outcom
tumorload
lung
sirna
target
nanoparticl
significantli
reduc
tumor
load
compar
untreat
control
p
therapeut
outcom
also
analyz
term
anim
surviv
day
surviv
rate
therapeut
sirna
control
sirna
target
nanoparticl
respect
mean
surviv
time
day
respect
p
furthermor
demonstr
therapeut
dose
mgkg
target
nanoparticl
induc
signific
product
analyz
cytokin
includ
even
two
consecut
inject
level
significantli
elev
therapeut
dose
none
formul
caus
elev
cytokin
product
lung
addit
bodi
weight
significantli
decreas
treatment
therapeut
dose
target
nanoparticl
formul
damag
major
organ
heart
liver
spleen
lung
kidney
sinc
selfassembl
nanoparticl
requir
presenc
high
molecular
weight
polyanion
stabil
calf
thymu
dna
initi
use
carrier
sirna
low
molecular
weight
nucleic
acid
calf
thymu
dna
foreign
dna
human
may
caus
unwant
toxic
immun
stimul
plasmid
dna
contain
high
amount
unmethyl
cpg
motif
hostil
cell
recent
success
replac
calf
thymu
dna
high
molecular
weight
anion
polysaccharid
ie
hyaluron
acid
result
formul
contain
cation
liposom
protamin
hyaluron
acid
call
lph
lph
show
gene
silenc
activ
correspond
lpd
formul
ed
luciferas
silenc
melanoma
model
sirna
lpd
formul
howev
induct
cytokin
lph
significantli
lower
correspond
lpd
contain
calf
thymu
dna
sinc
discoveri
rna
interfer
research
group
worldwid
sought
invent
effici
deliveri
system
enhanc
abil
sirna
travers
cell
membran
elicit
biolog
respons
wide
use
sirna
deliveri
methodolog
consist
cation
lipid
andor
cation
polym
packag
sirna
stabl
nanoparticl
capabl
transloc
across
cellular
membran
encapsul
sirna
nake
nanoparticl
dramat
increas
intracellular
deliveri
gene
silenc
activ
chargecharg
interact
formul
endosom
membran
pegyl
nake
nanoparticl
abolish
nonspecif
interact
neg
charg
cell
protein
also
enhanc
uptak
sirna
tumor
due
epr
effect
introduct
target
ligand
distal
end
peg
chain
restor
intracellular
deliveri
receptor
posit
cell
tissu
select
maintain
target
nanoparticl
formul
improv
tissu
specif
deliveri
effici
silenc
target
gene
lung
metastasi
effect
without
signific
immunotox
immunotox
nanoparticl
reduc
replac
high
molecular
weight
dna
hyaluron
acid
therefor
conclud
sirna
formul
target
nanoparticl
potenti
becom
use
tool
clinic
cancer
therapi
almost
ideal
specif
rnai
entir
true
realiti
silenc
offtarget
clearli
unwant
importantli
offtarget
effect
remain
critic
issu
therapeut
applic
rnai
hope
novel
protein
array
technolog
provid
better
pictur
sirna
effect
cellular
protein
express
profil
provid
better
way
screen
sirna
develop
indentifi
potent
hyper
function
sirna
help
resolv
unwant
offtarget
sinc
sirna
work
subnanomolar
concentr
likewis
intellig
effect
design
sirna
improv
strand
select
may
possibl
significantli
avoid
offtarget
effect
knowledg
immun
stimulatori
properti
call
research
proceed
anim
model
vitro
use
human
primari
cell
full
repertoir
immun
stimul
also
need
long
dsrna
would
induc
interferon
respons
bind
doublestrandedrnaactiv
protein
kinas
pkr
synthetas
rnase
l
system
sever
tolllik
receptor
tlr
particular
sequenc
motif
gurich
region
cpg
motif
stimul
innat
immun
respons
recent
dharmacon
publish
even
short
nt
long
sirna
may
invok
interferon
respons
cell
cultur
assay
great
care
thorough
test
clearli
need
proceed
clinic
use
importantli
length
threshold
seem
vari
among
cell
type
make
hard
predict
outcom
dicer
substrat
vivo
schemat
depict
structur
compon
requir
target
cation
complex
nanoparticl
sirna
deliveri
vivo
optim
design
formul
sirna
cross
endosom
membran
provid
sequencespecif
genesilenc
effect
similar
commerci
transfect
agent
polym
peptid
deliveri
system
sirna
endosom
escap
take
place
proton
spong
effect
improv
select
specif
deliv
sirna
vivo
ewe
sarcoma
mice
mous
brain
melanoma
xenograft
mice
condens
nanoparticl
sirna
modifi
target
element
receptor
mediat
uptak
surfac
modifi
lpd
nanopartcl
sirna
condens
protamin
form
core
wrap
cation
lipid
membran
final
pegyl
provid
surfac
protect
target
specif
oncogen
solid
metastat
tumor
effect
silenc
mous
model
high
tumor
uptak
low
immunotox
